April 4th Week, 2026 Regulatory Events 🎯 The EC granted conditional marketing authorization to Ipsen’s tovorafenib (Ojemda; type II RAF kinase inhibitor) monotherapy for the treatment of pediatric low-grade-glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (Ref 1) ❓ What is the addressable market for pLGG in EU? 🎯 The US FDA accepted a supplemental BLA for Pfizer and Astellas Pharma’s

22/04/2026 EC Grants Conditional Approval for Ojemda® in Relapsed/Refractory Pediatric Low‑Grade Glioma EC Grants Conditional Approval for Ojemda® in Relapsed/Refractory Pediatric Low‑Grade Glioma (Ref) The European Commission granted conditional marketing authorization for Ojemda® (tovorafenib) as the first targeted therapy for relapsed/refractory pediatric low‑grade glioma (pLGG), regardless of BRAF alteration. Scope: Applies to patients aged ≥6 months across all 27 EU Memb